Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Transduction01:16

Transduction

42
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome...
42
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers.

Cell death and differentiation·2026
Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026
Same author

Editor's Note: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Cancer research·2026
Same author

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.

Pigment cell & melanoma research·2026
Same author

Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.

Cancer immunology research·2025
Same author

Aqueous humor biomarkers in ocular oncology: Insights and advances.

Cell reports. Medicine·2025

相关实验视频

Updated: Jul 20, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

针对TEAD-ious的阻力

Connor A Ott1, Andrew E Aplin2

  • 1Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Trends in cancer
|August 5, 2023
PubMed
概括

通过向TEAD转录因子,可以克服对KRAS抑制剂的耐药性. 一种新的TEAD抑制剂GNE-7883可能会提高癌症患者的KRAS抑制剂的耐用性.

关键词:
在G12C中,G12C是指G12C.克拉斯 (Kras) 是一个国家.塔兹塔兹是什么意思?塔兹塔兹是什么意思我们的 TEAD TEAD 团队.这是一种TEAD抑制剂.哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈哈药物耐受性 耐药性 药物耐受性电阻的电阻是指电阻的电阻

更多相关视频

Protocols for Robust Herbicide Resistance Testing in Different Weed Species
10:52

Protocols for Robust Herbicide Resistance Testing in Different Weed Species

Published on: July 2, 2015

14.7K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.2K

相关实验视频

Last Updated: Jul 20, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K
Protocols for Robust Herbicide Resistance Testing in Different Weed Species
10:52

Protocols for Robust Herbicide Resistance Testing in Different Weed Species

Published on: July 2, 2015

14.7K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.2K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 向KRAS突变是癌症治疗的一个关键策略.
  • 对KRAS抑制剂的耐药性仍然是一个重大的临床挑战.
  • 该KRAS信号通路对于癌细胞的增殖和生存至关重要.

研究的目的:

  • 研究向TEAD转录因子以克服对KRAS抑制剂的耐药性的潜力.
  • 在临床前癌症模型中评估一种新型TEAD抑制剂GNE-7883的疗效.
  • 探索TEAD在调解对KRAS向疗法的耐药性的作用.

主要方法:

  • 使用了一种新型抑制剂GNE-7883,向TEAD转录因子.
  • 在相关的癌症模型中进行了研究,显示了KRAS突变和耐药性.
  • 评估GNE-7883对KRAS信号通路和瘤生长的影响.

主要成果:

  • GNE-7883在克服对现有KRAS抑制剂的耐药性方面表现出有效性.
  • 通过GNE-7883抑制TEAD信号传递显示出抗瘤活性.
  • 该研究提供了结合KRAS和TEAD抑制剂的治疗潜力的证据.

结论:

  • 像GNE-7883这样的TEAD抑制剂是提高KRAS抑制剂耐久性的有希望的策略.
  • 向TEAD转录因子可以克服癌症中对KRAS向疗法的获得性耐药性.
  • 对于KRAS突变癌症患者,需要对TEAD抑制剂进行进一步的临床研究.